Equibles does not estimate personal net worth.
Get an email with a short summary when Gain Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get GANX alertsGene Mack is recorded as CFO at Gain Therapeutics, Inc. (GANX) since April 8, 2024 and Board Member and CEO at Gain Therapeutics, Inc. (GANX). The newest filing on record that lists Gene Mack as Board Member and CEO at Gain Therapeutics, Inc. (GANX) is dated April 28, 2026. Gain Therapeutics, Inc. reported in an 8-K filed September 28, 2026 that Gene Mack was appointed interim Chief Financial Officer, effective October 1, 2026. Gain Therapeutics, Inc. reported in an 8-K filed January 7, 2025 that Gene Mack resigned as Chief Financial Officer, effective January 6, 2025. Gain Therapeutics, Inc. reported in an 8-K filed January 7, 2025 that Gene Mack was appointed member of the Company’s board of directors, effective January 6, 2025. Equibles holds 7 filed executive changes naming Gene Mack; each is listed under recent activity with its source filing. Gene Mack has spoken on 1 investor event across 1 company, most recently for Gain Therapeutics, Inc. on February 25, 2026. Gain Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Gain Therapeutics, Inc. includes Gene Mack, MBA (CEO, CFO and Board Member), Matthias Alder (CEO, COO and Board Member), Dr. Khalid Islam (Chairman) and 3 others.
“On September 24, 2026, the Company's board of directors appointed Gene Mack, the Company's current President and Chief Executive Officer, to serve as the Company's interim Chief Financial Officer, effective as of October 1, 2026.”
“Mr. Mack resigned from his position as Chief Financial Officer upon his appointment as Chief Executive Officer.”
“We're really pleased to be here. to get an opportunity to talk about our progress at Gain Therapeutics. So I'm just going to dive right in. So Gain Therapeutics, just to give folks an idea who are not familiar with the company, was established in 2017 and went public in 2021.”
2024-04-08–present
SEC 8-K
2024-04-08–present
Start not stated–present
Last confirmed April 28, 2026
Start not stated–present
Last confirmed April 28, 2026
2024-04-08–2025-01-06
Start not stated–2025-01-07
Biotechnology · Healthcare
Board Member, CEO, CFO
2024-04-08–present
